January 16, 2023
AbbVie launched a new 600 mg intravenous drip infusion version of its IL-23 inhibitor Skyrizi (risankizumab) in Japan on January 13 for the treatment of moderately to severely active Crohn’s disease inadequately controlled with existing therapies. The new formulation was...read more